Bill Newlin

SpIntellx harnesses the computational power of proprietary unbiased spatial analytics, spatial systems pathology, and explainable artificial intelligence (xAI) to extract information from patient primary disease pathology samples to create predictive knowledge that is required to develop personalized therapeutic strategies, identify potential novel targets for drug discovery, optimally select patient cohorts for clinical trials and improve the predictive power of prognostics/diagnostics.